Oventus Medical has entered into a collaboration agreement with Chinese company Zhuhai Blue Ocean Strategy Medical (ZHBOS).
The collaboration agreement executed between the companies relates to Oventus’ O2Vent T product, indicated for use during sleep to aid in the treatment of snoring and obstructive sleep apnoea (OSA).
The agreement details terms around clinical trials, training of relevant staff, achievement of relevant regulatory clearances and marketing preparations, as they pertain to the Chinese market.
ZHBOS has 633 network hospitals, spread throughout China in over 400 cities. Many of the hospitals have ENT sleep clinics some of which offer Continuous Positive Airway Pressure (CPAP) as the first line of treatment.
Oventus’ O2Vent T device is an alternative to CPAP particularly advantaging patients with nasal obstruction, or those that cannot tolerate, or who refuse CPAP. It is estimated that the Chinese market has in excess of 70 million OSA sufferers, and that OSA is likely to be a growing problem due to the effects of an ageing population and similar health factors afflicting western countries, such as obesity.
Luo Zhilin, chairman and CEO of Zhuhai Blue Ocean Strategy, said: “We have a demonstrated track record in introducing new clinical solutions to hospitals, and therefore for the patients they treat. This success has facilitated our significant growth to date. We believe the Oventus O2Vent T device is a clinical solution that will meet the needs of the Chinese population and there is a significant opportunity for an innovative oral appliance to enter our market, especially with the growing prevalence of sleep apnoea in China. We look forward to working with Oventus Medical on this important project.”